MOLECULAR DOCKING STUDIES AND ADME PREDICTION OF NOVEL ISATIN ANALOGS AS HIV-1-RT INHIBITORS WITH BROAD SPECTRUM CHEMO THERAPEUTIC PROPERTIES
Abstract
Molecular docking studies were performed on 100 newly designed isatin analogs by using Glide v 5.0 on the active site of four different enzymes namely HIV-1 reverse transcriptase (PDB ID 1RT2), glucosamine 6-phosphate (GlcN6P) (PDB ID 2VF5), mycobacterium tuberculosis-CYP51 (PDB code 1EA1) and candida albicans (CACYP51) (PDB code chimeric-1EA1) to study the binding mode of these analogs to study the binding mode of these analogs. Binding mode analysis of the compounds with the highest docking scores (-8.31,-5.90,-7.16,-6.395 and -8.14) was carried out and were compared with that of the co crystallized ligands TNK651, glucosamine (GLP) and fluconazole(TPF) in the active sites of 1RT2, 2VF5,1EA1 , and chimeric 1EA1respectively. ADME properties of all the newly designed isatin analogs 1-100 was calculated by Qik Prop v3.0. All the designed compounds were found to exhibit lead like properties from the calculated ADME properties. Results of these docking analyses can be well used for the design and development of novel isatin analogs possessing HIV-1- RT inhibitory activity with broad spectrum chemotherapeutic properties.
Â
KEYWORDSIsatin analogs, Docking, HIV, NNRTIs , NNIBP , Lipinski's rule ,ADMEDownloads
References
Catalan J, Collins P, Mash B, Freeman M. Mental Health and HIV/AIDS: Psychotherapeutic Interventions in Antiretroviral (ARV) Therapy for Second Level Care. Johannesburg, South Africa: WHO; 2005.
Gonda MA, Braun MJ, Clements JE, Pyper JM, Wong-Staal F, Gallo RC, et al. Human T-cell lymphotropic virus type III shares sequence homology with a family of pathogenic lentiviruses. Proc Natl Acad Sci U S A 1986;83(11):4007-11.
Gonda MA, Wong-Staal F, Gallo RC, Clements JE, Narayan O, Gilden RV. Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science 1985;227(4683):173 7.
UNAIDS/WHO. AIDS Epidemic Update, 2007. Available from: http://www.data.unaids.org. [Last accessed on 2014 Mar 12].
UNAIDS/WHO. Report on the Global AIDS Epidemic, 2008. Available from: http://www.unaids.org/en/KnowledgeCenter/HIVData/GlobalReport/2008/2008 Global report.asp. [Last accessed on 2014 Mar 12].
Ghosh TK. AIDS: A serious challenge to public health. J Indian Med Assoc 1986;84(1):29-30.
Zeng M, Paiardini M, Engram JC, Beilman GJ, Chipman JG, Schacker TW, et al. Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood 2012;120(9):1856-67.
Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions. Clin Infect Dis 2008;47(4):542-53.
Beale MJ Jr, Block JH. Wilson and Gisvold’s Text Book of Organic Medicinal and Pharmaceutical Chemistry. 12th ed. New York: Lippincott William Sons Publishers; 2011. p. 347.
Snider DE, Raviglione M, Kochi A. Global burden of tuberculosis. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology; 1994. p. 3-11.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282(7):677-86.
WHO. Global Tuberculosis Report, 2013. Available from: http://www.who.int/tb/publications/global_report/gtbr13_main_text.pdf. [Last accessed on 2014 Jun 14].
Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: Clinical manifestations and treatment. Clin Infect Dis 2010;50 Suppl 3:S223-30.
Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362(8):697-706.
Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004;59(8):704-7.
WHO. Global Tuberculosis Control: A Short Update to the 2009 Report. Geneva: World Health Organization; 2009. Available from: http://www.whqlibdoc.who.int. [Last accessed on 2014 Jun 12].
Elzinga G, Raviglione MC, Maher D. Scale up: Meeting targets in global tuberculosis control. Lancet 2004;363(9411):814-9.
Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24(1):71-109.
Yu D, Huiyuan G. Synthesis and antibacterial activity of linezolid analogues. Bioorgan Med Chem Lett 2002;12(6):857-9.
Koca M, Servi S, Kirilmis C, Ahmedzade M, Kazaz C, Ozbek B, et al. Synthesis and antimicrobial activity of some novel derivatives of benzofuran: Part 1. Synthesis and antimicrobial activity of (benzofuran-2-yl) (3-phenyl-3-methylcyclobutyl) ketoxime derivatives. Eur J Med Chem 2005;40(12):1351-8.
Rippon JW. Monitored environment system to control cell growth, morphology, and metabolic rate in fungi by oxidation-reduction potentials. Appl Microbiol 1968;16(1):114-21.
Lagoja IM, Pannecouque C, Van Aerschot A, Witvrouw M, Debyser Z, Balzarini J, et al. N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action. J Med Chem 2003 10;46:1546-53.
Ganguly S, Debnath B. Molecular docking studies and adme prediction of novel Isatin analogs with potent anti-EGFR activity. Med Chem 2014;4:558-68.
Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis antibacterial, antifungal and anti HIV activity of Schiff’s and Mannich bases of isatin with N-[6-chlorobenz thiazole-2-yl] thiosemicarbazide. Indian J Pharm Sci 1999;61:358-61.
Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin mannich bases. Eur J Med Chem 2000;35(2):249-55.
Sarangapani MR, Reddy VM. Pharmacological evaluation of 1-(N,N-disubstituted aminomethyl)-3-imino-(2-phenyl-3,4-dihydro-4-oxo-quinazolin-3-yl) indolin-2-ones. Indian J Pharm Sci 1994;56:174-7.
Varma RS, Nobles WL. Antiviral, antibacterial, and antifungal activities of isatin N-Mannich bases. J Pharm Sci 1975;64(5):881-2.
Sridhar SK, Saravanan M, Ramesh A. Synthesis and antibacterial screening of hydrazones, Schiff and Mannich bases of isatin derivatives. Eur J Med Chem 2001;36(7-8):615-25.
Logan JC, Fox MP, Morgan JH, Makohon AM, Pfau CJ. Arenavirus inactivation on contact with N-substituted isatin beta-thiosemicarbazones and certain cations. J Gen Virol 1975;28(3):271 83.
Varma RS, Nobles WL. Synthesis and antiviral and antibacterial activity of certain N-dialkylaminomethylisatin beta-thiosemicarbazones. J Med Chem 1967;10(5):972-4.
Singh SP, Shukla SK, Awasthi LP. Synthesis of some 3-(40-nitrobenzoylhydrazone)-2- indolinones as potential antiviral agents. Curr Sci 1983;52(16):766-9.
Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharm Acta Helv 1999;74(1):11-7.
Pandeya SN, Yogeeswari P, Sriram D, de Clercq E, Pannecouque C, Witvrouw M. Synthesis and screening for anti-HIV activity of some N-Mannich bases of isatin derivatives. Chemotherapy 1999;45(3):192 6.
Khan KM, Khan M, Ali M, Taha M, Rasheed S, Perveen S, et al. Synthesis of bis-Schiff bases of isatins and their antiglycation activity. Bioorg Med Chem 2009;17(22):7795-801.
Verma M, Pandeya SN, Singh KN, Stables JP. Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharm 2004;54:49-56.
Smitha S, Pandeya SN, Stables JP, Ganapathy S. Anticonvulsant and sedative-hypnotic activities of N-acetyl/methyl isatin derivatives. Sci Pharm 2008;76:621.
Venkateshwarlu E, Rao JV, Umasankar K, Dheeraj G. Study of anti-inflammatory, analgesic and antipyretic activity of novel isatin derivatives. Asian J Pharm Clin Res 2012;5(4):187-90.
Chandra PM, Venkateshwar J. Biological evaluation of Schiff bases of new isatin derivatives for anti Alzheimer’s activity. Asian J Pharm Clin Res 2014;7(2):114-7.
Bhattacharya SK, Chakrabarti A. Dose-related proconvulsant and anticonvulsant activity of isatin, a putative biological factor, in rats. Indian J Exp Biol 1998;36(1):118-21.
Matesic L, Locke JM, Bremner JB, Pyne SG, Skropeta D, Ranson M, et al. N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorg Med Chem 2008 15;16:3118-24.
Hossain MM, Islam N, Khan R, Islam M. Cytotoxicity study of dimethylisatin and its heterocyclic derivatives. Bangladesh J Pharmacol 2008;2:66-70.
Vine KL, Locke JM, Ranson M, Pyne SG, Bremner JB. In vitro cytotoxicity evaluation of some substituted Isatin derivatives. Bioorgan Med Chem 2007;15:931-8.
Pervez H, Ramzan M, Yaqub M, Mohammed Khan K. Synthesis, cytotoxic and phytotoxic effects of some new N4-aryl substituted isatin-3-thiosemicarbazones. Lett Drug Des Discov 2011;8:452-8.
Shuttleworth SJ, Nasturica D, Gervais C, Siddiqui MA, Rando RF, Lee N. Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett 2000;10(22):2501-4.
Jones G, Willett P. Docking small-molecule ligands into active sites. Curr Opin Biotechnol 1995;6:652-6.
Muegge I, Rarey M. Small molecule docking and scoring. Rev Comput Chem 2001;17:1-60.
Krovat EM, Steindl T, Langer T. Recent advances in docking and scoring. Curr Comput Aided Drug Des 2005;1:93-102.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. Method and assessment of docking accuracy. J Med Chem 2004;47:1739-49.
Available from: http://www.rcsb.org/pdb. [Last accessed on 2014 Mar 14].
Vijesh AM, Isloor A, Telkar S, Arulmoli T. Molecular docking studies of some new imidazole derivatives for antimicrobial properties. Arab J Chem 2013;6(2):197-204.
Yoshida Y, Aoyama Y. Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. I. Purification and spectral properties. J Biol Chem 1984;259(3):1655-60.
Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Purification and properties of cytochrome P-450-dependent 14 alpha-sterol demethylase from Candida albicans. Biochem J 1989;263(2):573 9.
Rossello A, Bertini S, Lapucci A, Macchia M, Martinelli A, Rapposelli S, et al. Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem 2002;45(22):4903-12.
Carlson HA, Masukawa KM, McCammon JA. Method for including the dynamic fluctuations of a protein in computer-aided drug design. J Phys Chem 1999;103:10213-9.
Carlson HA, Masukawa KM, Rubins K, Bushman FD, Jorgensen WL, Lins RD, et al. Developing a dynamic pharmacophore model for HIV-1integrase. J Med Chem 2000;43(11):2100-14.
Schrodinger, LLC. New York, USA: Schrodinger Inc.; 2008.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012;64:4-17.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.